Latest News - Phase 3/4 Trials

Tuesday, December 04, 2018 | Phase 3/4 Trials,

Revance Shares Positive Efficacy and Duration Data for RT002

Revance Therapeutics, Inc.'s long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results …

Read the full story

Wednesday, November 07, 2018 | Phase 3/4 Trials, Research and Publications

CCH Improves Appearance of Cellulite in Buttocks

Endo International plc’s clostridium histolyticum (CCH) performed well in two identical Phase 3 studies for the treatment of cellulite in the buttocks. Subjects receiving CCH showed highly st…

Read the full story

Thursday, October 11, 2018 | Personnel/Company News, Phase 3/4 Trials,, Research and Publications, Galderma

Galderma Announces the Start of Six New Aesthetic Studies

Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology p…

Read the full story

Tuesday, September 18, 2018 | FDA Approval/Clearance, Phase 3/4 Trials,,

New for EBD-Based Acne Care: Sebacia Microparticles Cleared

Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Se…

Read the full story

Monday, July 23, 2018 | Personnel/Company News, Phase 3/4 Trials,,, Research and Publications

First Patients Treated in Pulse Biosciences' Sebaceous Hyperplasia Study

Pulse Biosciences, Inc. says the first patients have been treated in its multi-center study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous…

Read the full story

Monday, April 30, 2018 | Phase 3/4 Trials,, Research and Publications

Jury Still Out on Cosmetic Uses of PRP

Most studies evaluating platelet-rich plasma (PRP) injection for facial rejuvenation and other cosmetic procedures have reported positive results, but the research evidence supporting PRP for facial a…

Read the full story

Monday, February 12, 2018 | Phase 3/4 Trials,, Product Launches and Updates

Denova Research Partners with Illinois Dermatology Institute

DeNova Research is partnering with Illinois Dermatology Institute to become one of the largest and most comprehensive Dermatologic and Cosmetic Clinical Research sites in the Midwest. Denova Resear…

Read the full story

Tuesday, December 05, 2017 | Phase 3/4 Trials,, Research and Publications

Investigational Neurotoxin Achieves 6-Month Duration in Phase 3: Revance

Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivota…

Read the full story

Thursday, April 06, 2017 | Phase 3/4 Trials,, Galderma

Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit in Phase 4 Studies

Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that…

Read the full story